EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma

Chijioke Nze iD, Pavlos Msaouel iD, Mohamed H Derbala, Bettzy Stephen iD, Abdulrahman Abonofal, Funda Meric-Bernstam, Nizar M Tannir, Aung Naing

Cancers · 27.07.2023 · 15 (15) · 3806

DOI: 10.3390/cancers15153806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 27.07.2023. Verfasst von Chijioke Nze und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, United States Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal medullary carcinoma (RMC) is one of most aggressive renal cell carcinomas and novel therapeutic strategies are therefore needed. Recent comprehensive molecular and immune profiling of RMC tissues revealed a highly inflamed phenotype, suggesting the potential therapeutic role for immune checkpoint therapies. We present the first prospective evaluation of an immune checkpoint inhibitor in a cohort of patients with RMC.

Methods

A cohort of patients with locally advanced or metastatic RMC was treated with pembrolizumab 200 mg intravenously every 21 days in a phase II basket trial (ClinicalTrials.gov: NCT02721732). Responses were assessed by irRECIST. Tumor tissues were evaluated for PD-L1 expression and for tumor-infiltrating lymphocyte (TIL) levels. Somatic mutations were assessed by targeted next-generation sequencing.

Results

A total of five patients were treated. All patients had advanced disease, with the majority of patients (60%) having metastatic disease at diagnosis. All patients had rapid disease progression despite pembrolizumab treatment, with a median time to progression of 8.7 weeks. One patient (patient 5) experienced sudden clinical progression immediately after treatment initiation and was thus taken off trial less than one week after receiving pembrolizumab.

Conclusions

This prospective evaluation showed no evidence of clinical activity for pembrolizumab in patients with RMC, irrespective of PD-L1 or TIL levels.

Schlagwörter

Stichwörter der Autor:innen

SMARCB1immunotherapypembrolizumabrenal medullary carcinoma

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Medicine, Section of Hematology/Oncology, West Virginia University, Morgantown, WV 26506, USA.

ORCID-Profile: Chijioke Nze, Pavlos Msaouel, Bettzy Stephen

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • United States Department of Defense
  • Andrew Sabin Family Foundation Fellowship
  • Gateway for Cancer Research
  • Kidney Cancer Association
  • V Foundation
  • Renal Medullary Carcinoma Research Foundation

Zitieren

APA

Nze, C., Msaouel, P., Derbala, M. H., Stephen, B., Abonofal, A., Meric-Bernstam, F., Tannir, N. M., & Naing, A. (2023). A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers, 15(15), 3806. https://doi.org/10.3390/cancers15153806

Vancouver

Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, et al. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers. 2023;15(15):3806. doi:10.3390/cancers15153806

BibTeX
@article{Nze2023,
  author = {Nze, Chijioke and Msaouel, Pavlos and Derbala, Mohamed H and Stephen, Bettzy and Abonofal, Abdulrahman and Meric-Bernstam, Funda and Tannir, Nizar M and Naing, Aung},
  title = {A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {15},
  pages = {3806},
  doi = {10.3390/cancers15153806}
}
Kostenlos starten →